New positive phase 2 results from @Alkermes show that treatment with alixorexton led to statistically significant and dose-dependent improvements in sleep latency among patients with narcolepsy type 1.

BioXcel Therapeutics has submitted a pre-supplemental New Drug Application meeting package to the FDA for Igalmi in support of a label expansion for outpatient use for the acute treatment of agitation associated with bipolar disorders or schizophrenia.

The FDA Advisory Committee has voted against recommending brexpiprazole plus sertraline for PTSD.

"Is study 61 enough to overcome study 72? We are here today because these are difficult questions.".

On Trial 072, Brady shares she'd be "disappointed if 1 trial with an unusually large response to sertraline obstructs our ability to discuss and assess the entirety of the data presented today for a critically important disorder with significant unmet clinical needs.".

@arjavanbakht "Brexpiprazole plus sertraline is exciting option for PTSD," said Kathleen Brady, MD, PhD, when sharing clinical perspectives on brexpiprazole plus sertraline.

@arjavanbakht John Kraus, MD, PhD, concludes brexpiprazole plus sertraline shows "substantial efficacy."

@arjavanbakht John Kraus, MD, PhD, reviews the clinical data at the FDA Advisory Committee meeting for brexpiprazole.

Arash Javanbakht, MD, shares PTSD by the numbers at the FDA Advisory Committee meeting. @arjavanbakht

The FDA Advisory Committee will vote: Based on the available data presented, has the efficacy of brexpiprazole, when initiated concurrently with sertraline, been established for the treatment of PTSD?.

The FDA advisory committee is currently meeting to discuss the sNDA for brexpiprazole (Rexulti) tablets in combination with sertraline for the treatment of adults with PTSD. Psychiatric Times will provide all the latest updates:

There is no one-size-fits-all approach to treating Major Depressive .Disorder (#MDD). Watch now as Leslie Citrome, MD, delves into .Treatment-Emergent Sexual Dysfunction (TESD): PAID CONTENT FROM TAKEDA PHARMACEUTICALS.

Seaport Therapeutics just announced that the first patient has been dosed in the phase 2b BUOY-1 study of GlyphAllo in major depressive disorder with or without anxious distress. If successful, GlyphAllo could be a first-in-class treatment.

Serum drug levels offer essential insights into medication efficacy and patient responsiveness. Learn more in this month's editorial.

The FDA has granted Breakthrough Therapy designation to Transcend Therapeutics for their compound TSND-201 (methylone) for the treatment of PTSD.

RT @MarkLRuffalo: Introducing the Psychotherapy Special Report, included in this month's issue of @PsychTimes.

Johnson & Johnson has submitted an sNDA to the FDA based upon long-term data evaluating the safety and efficacy of lumateperone (Caplyta) for the prevention of relapse in schizophrenia.

Check out all the updates in the psychiatric treatment pipeline from 2025 Quarter 2!

The July issue of Psychiatric Times is now live! This month, we take closer look at GLP-1 receptor agonists for the treatment of mental disorders. Download the issue now and follow along as articles are shared throughout the month.

Wishing you a safe and reflective Fourth of July! ❤️🤍💙 .As we honor resilience and freedom today, we’re also reminded of the importance of protecting mental health: for ourselves, our patients, and our communities. #FourthOfJuly #IndependenceDay